SCHEMBL2933284

SCHEMBL2933284

COc1ccc(C=O)cc1C(=O)N(Cc1ccccc1)Cc1ccccc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.46
MAPK1 P28482 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
CYP2C9 P11712 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
BCHE P06276 2/20 0.41
MAOA P21397 2/20 0.41
ACHE P22303 2/20 0.41
MAOB P27338 2/20 0.41
LPAR1 Q92633 2/20 0.40
LPAR5 Q9H1C0 1/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6811278 0.90 KDM4E (0.46) TSHRMAPK1NPC1RAB9ANPSR1
SCHEMBL2929421 0.78 KDM4E (0.54) TSHRTDP1NPC1RAB9ANPSR1
SCHEMBL6805058 0.78 KDM4E (0.47) MEN1KMT2ATDP1NPC1RAB9A
SCHEMBL2928131 0.78 KDM4E (0.47) TSHRKDM4EMAOAMAOBALDH1A1
SCHEMBL2933286 0.75 CYP2C9 (0.43) TSHRMAPK1KMT2ANPC1RAB9A
SCHEMBL6375681 0.72 CYP2C9 (0.51) TSHRMAPK1MEN1KMT2ATDP1
SCHEMBL2928136 0.72 APP (0.47) NPC1RAB9ANPSR1CYP2C9KDM4E
SCHEMBL2930961 0.71 TSHR (0.52) TSHRMEN1KMT2ATDP1KDM4E
SCHEMBL2931028 0.70 ALDH1A1 (0.49) TSHRTDP1NPC1RAB9ANPSR1
SCHEMBL2926924 0.70 PTGER1 (0.51) TSHRKDM4EMAOAMAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313731-B1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT UCB SA (BE) 2010-09-29 EP disclosed
US-6740670-B2 SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2004-05-25 US disclosed
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-11-20 US disclosed
EP-1313731-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT Oxford GlycoSciences (UK) Limited (GB) 2003-05-28 EP disclosed
WO-2002022612-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent CYP3A7, TAS2R7, OXSR1 TSHR 220/4885MAPK1 2736/4885MEN1 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.